Announcement on Convening the Q3 2026 Performance Briefing
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
(603998)"HUNAN FANGSHENG PHARMACEUTICAL CO., LTD."Announcement on Convening the Q3 2026 Performance Briefing
Filed with SSE · Stock code 603998 ·
6ix is reading this filing.
View original source (Shanghai Stock Exchange)Hunan Fangsheng Pharmaceutical Co., Ltd. on 6ix
Story so far
- (603998)"HUNAN FANGSHENG PHARMACEUTICAL CO., LTD."Announcement on Receipt of Drug Registration Certificate for Cobamamide Capsules
- (603998)"HUNAN FANGSHENG PHARMACEUTICAL CO., LTD."Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2026
- (603998)"HUNAN FANGSHENG PHARMACEUTICAL CO., LTD."Notice on Convening the 2nd Extraordinary General Meeting in 2026
Earlier from Hunan Fangsheng Pharmaceutical
- (603998)"HUNAN FANGSHENG PHARMACEUTICAL CO., LTD."Announcement on Receipt of Drug Registration Certificate for Cobamamide Capsules
- (603998)"HUNAN FANGSHENG PHARMACEUTICAL CO., LTD."Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2026
- (603998)"HUNAN FANGSHENG PHARMACEUTICAL CO., LTD."Notice on Convening the 2nd Extraordinary General Meeting in 2026
- Announcement on Resolutions of the 6th Extraordinary Meeting of the 6th Board of Directors in 2026
- Announcement on Progress of Transfer of Certain Equity Interests in a Controlled Subsidiary and Introduction of Strategic Investors
Follow Hunan Fangsheng Pharmaceutical into a list and get an email when it puts out news.
Follow Hunan Fangsheng Pharmaceutical